- Home
- IBG vs CHEK Comparison
IBG vs CHEK Comparison
Compare IBG & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- CHEK
- Stock Information
- Founded
- IBG 2018
- CHEK 2004
- Country
- IBG Australia
- CHEK Israel
- Employees
- IBG N/A
- CHEK N/A
- Industry
- IBG Beverages (Production/Distribution)
- CHEK Medical Electronics
- Sector
- IBG Consumer Staples
- CHEK Health Care
- Exchange
- IBG Nasdaq
- CHEK Nasdaq
- Market Cap
- IBG 4.1M
- CHEK 4.0M
- IPO Year
- IBG 2024
- CHEK 2015
- Fundamental
- Price
- IBG $0.72
- CHEK $0.79
- Analyst Decision
- IBG Strong Buy
- CHEK
- Analyst Count
- IBG 1
- CHEK 0
- Target Price
- IBG N/A
- CHEK N/A
- AVG Volume (30 Days)
- IBG 12.0M
- CHEK 36.6K
- Earning Date
- IBG 05-15-2025
- CHEK 05-14-2025
- Dividend Yield
- IBG N/A
- CHEK N/A
- EPS Growth
- IBG N/A
- CHEK N/A
- EPS
- IBG N/A
- CHEK N/A
- Revenue
- IBG $3,147,763.00
- CHEK N/A
- Revenue This Year
- IBG N/A
- CHEK N/A
- Revenue Next Year
- IBG N/A
- CHEK N/A
- P/E Ratio
- IBG N/A
- CHEK N/A
- Revenue Growth
- IBG N/A
- CHEK N/A
- 52 Week Low
- IBG $0.44
- CHEK $0.56
- 52 Week High
- IBG $3.35
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- CHEK 57.41
- Support Level
- IBG N/A
- CHEK $0.65
- Resistance Level
- IBG N/A
- CHEK $0.71
- Average True Range (ATR)
- IBG 0.00
- CHEK 0.06
- MACD
- IBG 0.00
- CHEK 0.01
- Stochastic Oscillator
- IBG 0.00
- CHEK 58.20
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.